Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 19/20 | 0.73 |
| ▸ | TTK | P33981 | 4/20 | 0.73 |
| ▸ | CSF1R | P07333 | 2/20 | 0.73 |
| ▸ | AURKA | O14965 | 2/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781846 | 0.86 | PRKDC (0.62) | PRKDCTTKCSF1RAURKAPIK3CA | |
| SCHEMBL23948209 | 0.84 | PRKDC (0.69) | PRKDCTTKCSF1RPIK3CAMTOR | |
| SCHEMBL29502021 | 0.83 | PRKDC (1.00) | PRKDCTTKCSF1RAURKAPIK3CA | |
| SCHEMBL23948252 | 0.83 | PRKDC (1.00) | PRKDCTTKCSF1RAURKAPIK3CA | |
| SCHEMBL1781471 | 0.82 | PRKDC (0.62) | PRKDCTTKCSF1RAURKAPIK3CA | |
| SCHEMBL25057401 | 0.82 | PRKDC (0.74) | PRKDCTTKCSF1RAURKAPIK3CA | |
| SCHEMBL26160047 | 0.79 | PRKDC (0.75) | PRKDCTTKCSF1RPIK3CAMTOR | |
| SCHEMBL23948207 | 0.78 | PRKDC (0.74) | PRKDCTTKCSF1RPIK3CAMTOR | |
| SCHEMBL29502027 | 0.78 | PRKDC (0.74) | PRKDCTTKCSF1RPIK3CAMTOR | |
| SCHEMBL23948263 | 0.77 | PRKDC (0.73) | PRKDCTTKCSF1RPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | PRKDC 163/4885TTK 4/4885CSF1R 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.